Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Oncolytic prodrug BMS-817378 selected for clinical development

Dec. 7, 2010

Merck KGaA divulges novel inhibitors of protein kinases

Dec. 7, 2010

TAvi6, a bispecific antibody targeting VEGF-A/ANG-2 inhibits angiogenesis in vivo

Dec. 3, 2010

Ascenta Therapeutics and Ascentage Pharma form alliance for cancer programs

Dec. 3, 2010

GenSpera adds trial site to G-202 phase I clinical program

Dec. 3, 2010

Chugai Pharma presents in vivo data on new potential cancer therapeutics

Dec. 3, 2010

Agennix discloses interim data from first-in-human trial of RGB-286638 in hematologic tumors

Dec. 3, 2010

Oncolytics Biotech begins enrollment in phase II Reolysin study in ovarian cancer

Dec. 2, 2010

FDA to request further information for Cavatak IND for phase II melanoma trial

Dec. 2, 2010

Medivation and Astellas complete enrollment in phase III MDV-3100 trial

Dec. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.